Analysis of DNA Methylation in Plasma for Monitoring Hepatocarcinogenesis
Authors:
- 1 June 2015
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 19 (6) , 295-302
Abstract
Aim: To explore whether the aberrant DNA methylation status in plasma could be used as a biomarker for hepatocellular carcinoma (HCC) screening among high-risk individuals. Methods: The promoter methylation status of ELF, RASSF1A, p16, and GSTP1 was investigated by methylation-specific polymerase chain reaction (PCR) in 34 paired HCC and nontumor liver tissue from HCC patients and 10 tissues from patients with liver cirrhosis (LC). Plasma samples from 31 HCC patients, 10 LC patients as well as 7 patients with benign hepatic conditions were also collected and characterized using the same method. Results: Among liver specimens, HCC tissues displayed a significantly higher methylation frequency of each gene compared with nontumor tissue (pp=0.001 and ppp400 level (serum alpha-fetoprotein [AFP] level at a cutoff of 400 ng/mL), the diagnostic sensitivity of HCC could increase to 93.55%. Conclusions: These results suggested that the methylation of tumor suppressor genes may participate in the development and progression of HCC. Additionally, it may be useful to combine the plasma DNA methylation status of a panel of gene markers and the serum AFP for HCC screening.Keywords
This publication has 42 references indexed in Scilit:
- BORIS, Brother of the Regulator of Imprinted Sites, Is Aberrantly Expressed in Hepatocellular CarcinomaGenetic Testing and Molecular Biomarkers, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Hepatic stem cells and transforming growth factor β in hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2012
- Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factorsHepatology, 2012
- CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor–Node–Metastasis Stage I Hepatocellular CarcinomaAnnals of Surgical Oncology, 2010
- The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signalingOncogene, 2009
- Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasionWorld Journal of Gastroenterology, 2009
- Quantitative Analysis of Circulating Methylated DNA as a Biomarker for Hepatocellular CarcinomaClinical Chemistry, 2008
- Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinomaHepatology, 2008
- Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the EsophagusClinical Cancer Research, 2006